AgeX Therapeutics, Inc.

75 articles with AgeX Therapeutics, Inc.

• AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

  5/17/2021

  AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2021.

• AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update

  3/31/2021

  AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the fourth quarter and the full year ended December 31, 2020.

• AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer

  3/12/2021

  AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer

• AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX’s Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and Obesity

  3/10/2021

  Research to utilize AgeX’s proprietary BAT cellular product candidate AgeX-BAT1. Loss of non-shivering thermogenic BAT, also known as brown or good fat, in humans with aging is associated with obesity, type II diabetes, and cardiovascular disease. Studies to evaluate if transplantation of AgeX-BAT1 in mice improves diet-induced obesity, metabolic health including glucose metabolism, and cardiac function.

• AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement

  3/2/2021

  AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. (“LyGenesis”), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they will proceed to negotiate an agreement

• AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only

  12/22/2020

  AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE) announced today that due to state and county government health orders, attendance at the AgeX 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to be held at 10:00 a.m. Pacific Standard Time on Monday, December 28, 2020 will be permitted only through online participation

• AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

  11/16/2020

  Sublicensed stem cell line ESI-053 to ImStem Biotechnology for development of cell therapy candidate IMS001 for COVID-19 and acute respiratory distress syndrome from other causes. Expanded agreement related to ESI clinical-grade pluripotent stem cell lines to provide AgeX independence to sublicense ESI lines to industry and academia for development of cellular therapeutics.

• AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome

  10/28/2020

  Emerging Preclinical and Clinical Data Support Potential of Mesenchymal Stem Cells (MSCs) to be Useful in COVID-19 and Acute Respiratory Distress Syndrome (ARDS) from Other Causes ImStem’s MSC Product Candidate IMS001 is Derived from AgeX’s Stem Cell Line ESI-053 IMS001, which Recently Gained FDA IND Clearance to Begin Human Study in Multiple Sclerosis, to be Considered for Development in COVID-19 and ARDS More Generally

• AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic Purposes

  9/9/2020

  AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a company focused on developing and commercializing innovative therapeutics for human aging, and Lineage Cell Th

• AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

  8/14/2020

  AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the second quarter ended June 30, 2020. AgeX made strides with respect to its newly established licensing and collaboration model, which aims to embed its technology platforms across the cell therapy industry. AgeX has entered into a rese

• AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications

  6/16/2020

  Allows industry and academia access to cGMP-grade, NIH-registered AgeX ESI human pluripotent stem cells for development of cellular therapeutics AgeX ESI cell lines are among only a few pluripotent stem cell lines from which derived cell therapy candidates have been granted FDA IND clearance to begin human trials Pluristyx will manufacture, market, and distribute Ready-to-Use™ and Ready-to-Differentiate™ ESI stem cell lines vialed and frozen o

• AgeX Therapeutics Receives Stock Exchange Deficiency Letter

  6/5/2020

  AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on June 1, 2020 AgeX received a Deficiency Letter from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that Age

• AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDS

  6/2/2020

  Emerging preclinical and clinical literature support MSCs may be appropriate to develop for COVID-19 as well as non-COVID-19 ARDS ImStem’s investigational MSC candidate IMS001, for which FDA recently removed a clinical hold on an IND to begin a human study in multiple sclerosis, to be considered for further development in COVID19 and ARDS from other causes IMS001 is derived from AgeX human embryonic stem cell line ESI 053

• AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A

  5/29/2020

  Sernova to utilize AgeX’s UniverCyte TM gene technology to generate transplantable, universal immune-protected therapeutic cells for Sernova’s Cell Pouch TM Platform ALAMEDA, Calif. & LONDON, Ontario--( BUSINESS WIRE )-- AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical-stage regenerative medicine th

• AgeX Therapeutics, Inc. Appoints Andrea Park as Chief Financial Officer

  5/21/2020

  AgeX Therapeutics , Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Andrea Park has been appointed Chief Financial Officer. Ms. Park replaces Russell Skibsted who served in that role since the Company was organized in 2017. Andrea Park served as our Vice

• AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update

  5/14/2020

  AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the first quarter ended March 31, 2020.

• AgeX Therapeutics Announces Reduction in Projected Cash Expenditures

  5/1/2020

  AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced that based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets resulting from the COVID-19 pandemic,

• AgeX Therapeutics Reports Fourth Quarter and Annual 2019 Financial Results and Provides Business Update

  3/30/2020

  AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the fourth quarter and year-end results for 2019.

• AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis

  3/20/2020

  AgeX Therapeutics , Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. (Farmington, CT), a biopharmaceutical company pioneering the development of mesenchymal stem cells (hES-MSC) derived from human embryonic stem cells has received notification from the U.S. Food and Drug Administration (FDA) th

• AgeX Therapeutics Researchers Publish Paper on the Age Reprogramming of Super-Centenarian Cells

  2/28/2020

  AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced a new paper co-authored by two AgeX scientists that could lead to new insights into the fundamental mechanisms of aging and why super-centenarians not only live the longest, but also experience extraordinary healthspans; an extension of the healthy years of life that compresses morbidity to a very short period near the end of life.